manilatimes29d
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). This is the first prospective randomized phase III study globally on a ...
NBC4 Columbus29d
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). This is the first prospective randomized phase III study globally on a HER2 ...
Medindia1mon
2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium ...
Mena FN29d
2024 Sabcsresults Unveiled For The Phase III Study Of Disitamab Vedotin In Treating HER2-Positive Advanced Breast Cancer With Liver Metastasis
of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). This is the first prospective randomized phase III study globally on a HER2 ...